![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » APHTON ANNOUNCES RESULTS FROM PHASE I WITH LEWIS Y
APHTON ANNOUNCES RESULTS FROM PHASE I WITH LEWIS Y
Aphton announced positive results from an open-label dose-escalating Phase I trial with IGN311, a humanized monoclonal antibody targeting the Lewis Y tumor-associated antigen.
Lewis Y is a factor known to be over-expressed in up to 90 percent of epithelial carcinomas, including breast, colon, gastric and pancreatic cancers. IGN311 is being developed as a potential new therapy for the treatment of Lewis Y positive tumors.
In this Phase I trial, IGN311 demonstrated favorable safety and tolerability, and advantageous pharmacokinetics with a serum half-life of more than 20 days. Data from the trial also indicate efficacy of IGN311 against Lewis Y-positive tumor cells circulating in peripheral blood. The number of such cells was significantly decreased in those patients that presented with detectable levels of such cells prior to first infusion.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct